ACE2 and chronic kidney disease: Moreover, ACE2 inhibition was reported to be associated with increasing albumin excretion and worsen glomerular injury (Soler, Wysocki, & Batlle, 2008), which was confirmed by an experimental study using exogenous human recombinant ACE2 to slow the progression of chronic kidney disease by reducing in albumin excretion (Oudit et al., 2010).